The HIV Wasting Syndrome

Wasting syndrome is defined as weight loss in excess of 10% from baseline that is associated with chronic diarrhea, fever, or weakness. Between 1987 and 1991, wasting was the second most common AIDS-associated condition reported to the CDC and the only AIDS-associated illness noted in 7.1% of reported cases. Unpublished data from the CDC's Adult-Adolescent Spectrum of Disease Program, which studied AIDS deaths in 10 cities, found that between 1990 and 1994, wasting occurred in 21.6% of cases. This was the fourth most common AIDS-associated condition, after PCP, MAC, and esophageal candidiasis. CDC statistics from 1995 document wasting as the third most common AIDS-indicator condition, after severe immunosuppression and PCP. Wasting is more prevalent in people of low socioeconomic status and women. For a variety of reasons, clinicians often treat wasting syndrome inadequately. They can be overwhelmed by the difficulties and competing side effects of antiretroviral regimens and OI therapies. Physicians receive very little nutrition education as part of their formal training. Additionally, effective pharmacologic intervention in wasting is just beginning to evolve.

The degree of wasting and malnutrition correlates with progression of AIDS. Data from the Multicenter AIDS Cohort Study showed that development of AIDS, fever, thrush, and a CD4 lymphocyte count of less than 100/mm3 were independently associated with continuing loss of body mass. Another study found that measurements of lean body mass, albumin, and transferring predict survival, independent of CD4 count. Starvation causes death when people reach 66% of ideal body weight or 54% of ideal body cell mass; patients with AIDS die at a similar level of weight loss. Because wasting is associated with disease progression, prevention and treatment of wasting should be an integral part of the care of patients infected with HIV. Studies are in progress to document the effect of reversing wasting on disease progression, morbidity and mortality.

Pathophysiology of Wasting:

Not all pathogenetic mechanisms of wasting in HIV have been fully elucidated, but many factors that promote progressive weight loss are understood. Wasting is a product of:  perturbations of metabolism and resting energy expenditure caused by the body's immunologic response to HIV and its secondary infections;  inadequate nutrition, secondary to poor oral intake, and malabsorption of nutrients, caused by diarrhea and alteration of levels of endogenous anabolic hormones, especially in men.

Perturbations of Metabolism: Resting energy expenditure (REE) increases with HIV infection. Even asymptomatic individuals with early infection have been shown to have an REE of 9% to 12% above seronegative controls. In HIV-associated hypermetabolism, maintenance of body weight requires an increase in caloric intake but, in the absence of OIs, most HIV-positive individuals can maintain adequate intake. Patients with AIDS have REEs of 25% to 34% above controls in some studies, and REE increases even when nutritional intake is poor. Paradoxically, in normal subjects REE decreases when caloric intake declines.

The development of an OI, with its concomitant rise in REE, usually leads to loss of weight, mostly lean body mass. Conversely, weight gain achieved through alimentation alone is mostly adipose tissue. This physiologic preference for fat over lean body mass is more acute in men than women, but all patients with AIDS face a persistent loss of lean body mass that is difficult to replace. The body, instead of reacting to a scarcity of nutrients by preserving lean body mass, combines hypermetabolism with accelerated protein breakdown and negative nitrogen balance to produce wasting.

Limited data are available on the potential role of cytokines in patients with AIDS and more research is needed. However, the mechanism of metabolic dysregulation that inappropriately increases REE and favors adipose tissue over lean body mass may in part be related to the cytokines elaborated in response to HIV and OIs. Tumor necrosis factor (TNF), interleukin (IL)  and 6 and interferon alpha, beta, and gamma have all been implicated in metabolic dysregulation. TNF induces weight loss and suppresses appetite in animal models. In addition, these various cytokines may act synergistically to cause futile cycling and inappropriate use of substrates.

Futile cycling of fat occurs in HIV infection, contributing to increased REE as well as hypertriglyceridemia. Peripheral lipolysis releases free fatty acids from adipose tissue. The free fatty acids are re-esterified into triglycerides in the liver and then packaged into very low density lipoproteins (VLDLs), which are released into circulation. The VLDLs are broken down in the periphery by lipoprotein lipase, resulting in storage of the triglycerides in peripheral adipose tissue again. Each of these steps requires adenosine triphosphate (ATP), thus wasting energy, shuttling fat between the periphery and the liver and back again. Current research concludes that TNF, IL-1, IL-6, and interferon alpha play a role in futile cycling of fat.

Inappropriate use of substrate contributes to increased REE and protein wasting seen in HIV. An example of this is the liver utilizing glucose to synthesize triglycerides, instead of protein, in individuals with negative nitrogen balance. This step consumes energy needed to maintain body cell mass. Using energy to make fat is inappropriate in a patient losing body cell mass. The body should be oxidizing fat, not synthesizing it, in this situation. Bodily energy reserves and substrate such as glucose should be employed to restore lean body mass. TNF, IL-1, IL-6, and interferon alpha appear to be involved in the transformation of glucose into triglycerides in the liver.

Malnutrition: Malnutrition occurs in HIV for many reasons. Both illness and inactivity suppress appetite. Many of the medications used to treat HIV and OIs cause anorexia and a variety of GI side effects. Candidiasis, aphthous ulcers, and CMV disease involving the mouth and esophagus make eating difficult and decrease oral intake.

Many secondary infections including MAC, CMV, cryptosporidium, microspora, protozoa, and bacterial pathogens cause diarrhea and secondary malabsorption of nutrients. HIV causes diarrhea through villous atrophy, crypt hyperplasia, lymphocyte infiltration of bowel epithelium, viral infiltration of the mucosae, and the development of an enteric autonomic neuropathy. Many of the well-known hepatic complications associated with HIV, as well as abnormalities of the pancreas caused by ddI, ddC, pentamidine, CMV, MAC, cryptococcus, toxoplasmosis, and TB contribute to diarrhea and malnutrition. Malnutrition is further exacerbated when patients decrease oral intake in an effort to reduce diarrhea.

Androgen Deficiency: One of the roles of androgenic hormones is to help generate and maintain lean body mass. More than half of men with AIDS have low or inadequate androgenic hormone levels due to HIV's interference with the hypothalamus-pituitary axis, adrenal glands, and the testes. Total and free testosterone levels are both suppressed. This lack of endogenous anabolic stimulation is particularly important in light of the metabolic shift away from preservation of lean body mass. HIV's effect on endogenous androgens in women has not been well studied. Given the high prevalence of wasting syndrome in women, both viral effects on female metabolism and the impact of hormone supplementation need further study.

Treatment of Wasting: Optimally, clinicians should try to prevent wasting syndrome as well as treat it when it occurs. Weight loss is often the first sign of a new AIDS-defining illness. Patients should be weighed at every visit and their weight trends recorded on a graph. Because lean body mass is lost in preference to fat, weight alone can be a misleading indicator of nutritional status and clinical course. Laboratory markers of nutritional status include albumin, transferrin, and cholesterol levels. Some clinicians also use bioelectric impedance analysis, which measures lean body mass, to track nutritional status.

Treating Underlying Illness: A crucial first step is to provide appropriate antiretroviral therapy as well as meticulous prophylaxis and treatment of OIs. Two early studies documented clinical and biochemical improvement in individuals treated with AZT monotherapy; one documented an average 2- to 3-kg weight gain and a second demonstrated rapid, significant, and sustained declines in interferon and triglyceride levels in subjects treated with AZT. A later study documented a decrease in REE of 650 kcal/day in patients with CMV colitis who were treated with ganciclovir. Several studies have documented that patients with active, untreated secondary infections are often unable to gain weight even with hyperalimentation.

Patients with untreated secondary infections involving the mouth and GI tract tend to have poor oral intake, since they often have dysphagia and odynophagia as well as diarrhea and malabsorption. Addressing oral and esophageal complications can improve caloric intake and reduce discomfort (see ACC, March 1995 for a complete discussion of esophageal lesions in HIV).

Nutrition: Maintenance of good nutrition is essential. Lost weight can be very difficult to replace. Calorie needs are in the 25 to 60 kcal/kg/day range; 20% should be protein. Working with a nutritionist is helpful. Patients often have deficiencies of micronutrients. One study found a 31% decrease in progression to AIDS in patients taking regular multivitamins with minerals. This finding may be confounded by a bias in favor of more compliant patients with better diets.

Oral feeding is clearly the nutritional route of choice. Emphasizing intake that is high in calories, protein, and fat is important. Over-the-counter nutritional supplements can help patients who are having difficulty with meals, or while they are being treated for oral or esophageal ulcers. Enteral alimentation can be used if oral or esophageal disease or disabling systemic illness makes eating temporarily impractical. Total parenteral nutrition (TPN) has been hotly debated in AIDS. Using TPN in patients with inadequately treated, active OIs and end-stage disease is of little value. Weight gained, if any, will be primarily fat. TPN is occasionally useful as temporary "bridge" therapy for a discrete period during treatment of intercurrent illness. The clear goal should be a restoration of full oral feeding once the patient can eat again. TPN is generally inappropriate in the terminal care of patients with AIDS.

The two main goals of HIV treatment

The only way to diagnose HIV is to take a test which looks for signs of the virus in the blood. Presence of the virus in the blood is termed as HIV positive (HIV+). If no signs of the virus are found in the blood, the result is considered negative. It is diagnosed on the basis of positive results from two different HIV tests.

The plasma HIV RNA test (a viral load test) is recommended when recent infection is suspected. The test detects the virus in the blood within 9 days of infection; before the body develops detectable antibodies to it.

Antibody tests: The antibody tests check for HIV antibodies that the body produces in response to the infection. In most people, antibodies to the virus are not detectable during a window period of 3 to 12 weeks after infection. Hence, a HIV antibody test is not useful during this period. Retesting should be done after three months to confirm the test results. Some of the antibody tests are as follows:

    Rapid HIV antibody test, the most common HIV test, is done using blood, urine or saliva and can produce results within an hour.
    Enzyme-linked immunosorbent assay is an antibody test that is usually the first one used to detect HIV infection. If the result is positive, the test is usually repeated to confirm the diagnosis.
    Western blot test is one of the oldest but most accurate confirmatory antibody tests. It is done to confirm the results of two positive ELISA tests

Polymerase chain reaction (PCR, a viral load test) test finds either the RNA or the DNA of the HIV in white blood cells even if other tests are negative for the virus. The PCR test is very useful to find a very recent infection, screen blood for HIV before donation and in babies born to mothers infected with the virus. Protein p24, the antigen on HIV that produces an antibody response in the body is produced in excess early in the infection. Antigen p24 tests detect these proteins in the blood. This test is usually not used for general HIV diagnostic purposes. HIV-infected people may not have any symptoms of disease for eight to ten years or longer (asymptomatic period). Their CD4 (T-cell) count should be watched closely during this time. If they have a CD4 count below 200 and if AIDS-related conditions appear, then they are considered to have AIDS.

The two main goals of HIV treatment are:

    to prevent the virus from damaging the immune system
    to halt or delay the progress of the infection

Antiretroviral (ARV) drugs are used for treating and preventing HIV infection. They stop or interfere with the reproduction of the virus in the body. HIV therapy includes combinations of drugs. Antiretroviral therapy (ART) consisting of combination of three or more antiretroviral drugs to suppress the virus. ART does not cure HIV infection. It controls replication of the virus thereby strengthening an individual’s immune system to fight off infections. These drugs must be taken at the right time every day. Incorrect or inconsistent therapy can mutate the virus causing resistance to treatment. In such cases, other medication options must be used. The amount of the virus in the blood (viral load) is measured to monitor the efficacy of the treatment. The goal of treatment is to get an undetectable viral load in lab tests.

There is no cure for HIV. But the progression of the virus in the body can be reduced to a near halt with continued adherence to appropriate antiretroviral therapy. If the infection has progressed to AIDS, treatment may also include drugs to fight and prevent the opportunistic infections.

People with HIV need counseling and psychosocial support in addition to antiretroviral treatment. A high quality of life needs to be maintained with basic hygiene, adequate nutrition and safe water. Testosterone levels decline naturally as a man gets older. Symptoms of low testosterone may appear earlier in some men. This is called hypogonadism and the symptoms include:

    Low libido or sex drive
    Erectile dysfunction or impotence
    Fatigue and lethargy
    Muscle weakness
    Shaving less often, loss of body hair
    Breast growth
    Reduced testicle size
    Skin changes on the skin, smooth, fine wrinkles

Living with HIV – diagnosis, treatment and prevention

The plasma HIV RNA test (a viral load test) is recommended when recent infection is suspected. The test detects the virus in the blood within 9 days of infection; before the body develops detectable antibodies to it. The only way to diagnose HIV is to take a test which looks for signs of the virus in the blood. Presence of the virus in the blood is termed as HIV positive (HIV+). If no signs of the virus are found in the blood, the result is considered negative. It is diagnosed on the basis of positive results from two different HIV tests.

Antibody tests: The antibody tests check for HIV antibodies that the body produces in response to the infection. In most people, antibodies to the virus are not detectable during a window period of 3 to 12 weeks after infection. Hence, a HIV antibody test is not useful during this period. Retesting should be done after three months to confirm the test results. Some of the antibody tests are as follows:

    Rapid HIV antibody test, the most common HIV test, is done using blood, urine or saliva and can produce results within an hour.
    Enzyme-linked immunosorbent assay (ELISA) is an antibody test that is usually the first one used to detect HIV infection. If the result is positive, the test is usually repeated to confirm the diagnosis.
    Western blot test is one of the oldest but most accurate confirmatory antibody tests. It is done to confirm the results of two positive ELISA tests

Polymerase chain reaction (PCR, a viral load test) test finds either the RNA or the DNA of the HIV in white blood cells even if other tests are negative for the virus. The PCR test is very useful to find a very recent infection, screen blood for HIV before donation and in babies born to mothers infected with the virus.

Protein p24, the antigen on HIV that produces an antibody response in the body is produced in excess early in the infection. Antigen p24 tests detect these proteins in the blood. This test is usually not used for general HIV diagnostic purposes.

HIV-infected people may not have any symptoms of disease for eight to ten years or longer (asymptomatic period). Their CD4 (T-cell) count should be watched closely during this time. If they have a CD4 count below 200 and/or if AIDS-related conditions appear, then they are considered to have AIDS.

The two main goals of HIV treatment are:

  -  to prevent the virus from damaging the immune system
  -  to halt or delay the progress of the infection

Antiretroviral (ARV) drugs are used for treating and preventing HIV infection. They stop or interfere with the reproduction of the virus in the body.

HIV therapy includes combinations of drugs. Antiretroviral therapy (ART) consisting of combination of three or more antiretroviral drugs to suppress the virus. ART does not cure HIV infection. It controls replication of the virus thereby strengthening an individual’s immune system to fight off infections. These drugs must be taken at the right time every day. Incorrect or inconsistent therapy can mutate the virus causing resistance to treatment. In such cases, other medication options must be used. The amount of the virus in the blood (viral load) is measured to monitor the efficacy of the treatment. The goal of treatment is to get an undetectable viral load in lab tests.

There is no cure for HIV. But the progression of the virus in the body can be reduced to a near halt with continued adherence to appropriate antiretroviral therapy. If the infection has progressed to AIDS, treatment may also include drugs to fight and prevent the opportunistic infections. People with HIV need counselling and psychosocial support in addition to antiretroviral treatment. A high quality of life needs to be maintained with basic hygiene, adequate nutrition and safe water.

Can treatment prevent HIV from advancing to AIDS? Treatment with anti-HIV medications prevents the virus from multiplying and destroying the immune system, thus helping the body fight off infections and cancers and preventing HIV from advancing to AIDS.

HIV-virus and making use of anabolic steroids

People who are suffering from the dreaded HIV-virus and making use of anabolic steroids to prevent AIDS wasting tend to gain modest gains in terms of muscle mass and weight, according to a new review.  Anabolic steroids are synthetic substances similar to the male sex hormone testosterone that promote growth of skeletal muscle and the development of male sexual characteristics. Although most recently in the news for their misuse by professional athletes, anabolic steroids have legitimate medical application for men with low testosterone and people with certain types of anemia. Two anabolic steroids available in the United States, Nandrolone Decanoate and Oxandrolone, have been used to help increase weight and muscle mass in small studies of people with wasting. Conversely, anabolic steroid use has been associated with increased rates of HIV in those who share needles or use non sterile needles when they inject steroids.

A synthetic anabolic steroid derived from Dihydrotestosterone, Winstrol or Stanozolol has been approved by the U.S. Food and Drug Administration for human use. This steroid with a high oral bioavailability survives first-pass liver metabolism when ingested because of a C17 a-alkylation.

Classified as a controlled substance under the Anabolic Steroids Control Act of 1990 and assigned to Schedule III, this drug has the chemical name of 17-methyl-2′ H -5(alpha)-androst-2-eno [3,2- c ]pyrazol-17(beta)-ol and the molecular weight of 344.5392 g/mol at the base.

Why Is Winstrol Used:
Winstrol is medically prescribed to treat anemia and hereditary angioedema. It is also recommended for improving muscle growth and increasing bone density. Winstrol may also be prescribed for improving the production of red blood cells in the body and stimulating the appetite of debilitated or weakened individuals. It may also be recommended to treat health conditions like urticaria, Raynaud’s phenomenon, cryptofibrinogenemia, and lipodermatosclerosis. Winstrol use can also be associated with strengthened tendons and ligaments and to increase lymphocyte count and CD8+ cell numbers and to decrease CD4+ and CD3+ in postmenopausal women who are diagnosed with autoimmune disorders or osteoporosis.

Winstrol is generally used by those into bodybuilding, athletics, and power lifting to lose fat while retaining lean muscle mass. Winstrol is commonly made a part of cutting cycles for preserving lean body mass while metabolizing adipose. Winstrol has the unique ability of reducing the level of sex hormone-binding globulin (SHBG) that binds to sex hormones for creating a positive and synergetic effect with other anabolic steroids used in an anabolic steroid cycle. This performance enhancing drug is also used by athletes to run faster and preserve muscle tissue during dieting. Winstrol is also admired in the bodybuilding circles for decreasing the level of high-density lipoproteins and increasing the level of low-density lipoproteins. This drug can even stimulate immediate-early gene expression in a manner that is independent of the androgen receptor.

In addition to these advantages, this drug is also used by athletes and bodybuilders because of its diuretic properties since Winstrol can improve the excretion of water from the body while improving body strength, without causing an increase in the level of body weight. Athletes absolutely admire this drug as it helps them utilize more amounts of testosterone for burning excess fat tissues and stimulates the production of prostaglandin E2 and the matrix metalloproteases collegenase and stromelysin in skin fibroblasts. The use of Winstrol can also be associated with the inhibition of growth factor stimulated DNA synthesis and fibroblasts.

Winstrol is ideally used by men in doses of 25-100 mg per day and 5-15 mg per day by women for a period not exceeding eight weeks at a stretch. This drug may be stacked for a bulking cycle with Testosterone, Dianabol or Anadrol or with Trenbolone or Halotestin during a dieting phase. A big majority of athletes even stack Winstrol with Equipoise, Deca Durabolin or Primobolan.